Pulse Biosciences, INC 8-K filings

NASDAQ

14 Feb 2024

PLSE

8-K: Pulse Biosciences Announces Positive Early Results in Atrial Fibrillation Study

Pulse Biosciences reports favorable 60-day follow-up data from initial patients in its CellFX nsPFA cardiac catheter study, showing promising results for atrial fibrillation treatment.